To evaluate the incidence of collateral vessel formation and to determine their impact on best-corrected visual acuity and central foveal thickness in patients with branch or central retinal vein occlusion (BRVO, CRVO) receiving 0.3 mg or 0.5 mg of ranibizumab, or sham.
This retrospective analysis was performed in patients with macular edema secondary to retinal vein occlusion who received 6 monthly intravitreal injections of ranibizumab (0.3 mg or 0.5 mg), or sham, followed by 6 months of as-needed treatment. Collateral vessel presence, change from baseline best-corrected visual acuity, and change from baseline central foveal thickness were assessed at baseline and months 3, 6, 9, and 12.
At month 12, 19.6% of BRVO patients receiving sham/0.5 mg and 16.7% receiving ranibizumab (0.3 mg and 0.5 mg pooled) manifested collaterals at the disk, whereas 48.2% and 47.2% displayed collaterals within the retina, respectively. In CRVO patients, 57.9% and 59.2% of all groups manifested collaterals on the disk, respectively, whereas 12.1% and 15.1% displayed collaterals within the retina. Mean best-corrected visual acuity gain in ranibizumab-treated BRVO and CRVO patients was similar, irrespective of collaterals within the retina (BRVO: P > 0.05; CRVO: P > 0.05).
The location of collaterals differed between retinal vein occlusion subtypes and ranibizumab treatment did not affect collateral vessel incidence. The presence of collaterals did not seem to impact best-corrected visual acuity gains at month 12 in both BRVO and CRVO patients receiving ranibizumab, whereas generally greater central foveal thickness reductions were observed with presence of collaterals in BRVO patients.
This retrospective analysis of two randomized controlled trials examined the presence of collateral vessels and their impact on best-corrected visual acuity in patients with branch or central retinal vein occlusion receiving 0.3 mg or 0.5 mg of ranibizumab or sham.
*Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio;
†Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio; and
‡Genentech Inc, South San Francisco, California.
Reprint requests: Rishi P. Singh, MD, Cole Eye Institute, Cleveland Clinic Main Campus, Mail Code I32, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: firstname.lastname@example.org
R. P. Singh is a consultant for and has received research support from Genentech, Inc, Regeneron, Alcon, and Thrombogenics. T. J. Lee does not have any financial disclosures. L. Yau and R. G. Rubio are employees of Genentech, Inc.